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For the 2003 monkeypox virus (MPXV) outbreak in 
the United States, interhuman transmission was not docu-
mented and all case-patients were near or handled MPXV-
infected prairie dogs. We initiated a case–control study to 
evaluate risk factors for animal-to-human MPXV transmis-
sion. Participants completed a questionnaire requesting 
exposure, clinical, and demographic information. Serum 
samples were obtained for analysis of immunoglobulin G 
(IgG) and IgM to orthopoxvirus. When data were adjusted 
for smallpox vaccination, case-patients were more likely 
than controls to have had daily exposure to a sick animal 
(odds ratio [OR] 4.0, 95% conﬁ  dence interval [CI] 1.2–13.4), 
cleaned cages and bedding of a sick animal (OR 5.3, 95% 
CI  1.4–20.7), or touched a sick animal (OR  4.0, 95% CI 
1.2–13.4). These ﬁ  ndings demonstrate that human MPXV 
infection is associated with handling of MPXV-infected ani-
mals and suggest that exposure to excretions and secre-
tions of infected animals can result in infection.
M
onkeypox (MPX) is a smallpox-like, but zoonotic, 
disease endemic to regions of West and Central Af-
rica. This disease results from infection with Monkeypox 
virus (MPXV) (1), a member of the genus Orthopoxvirus 
within the family Poxviridae (2). The principal animal res-
ervoir of MPXV is unknown, but varied sylvan species are 
susceptible to MPXV infection (3–6), and multiple species 
have been implicated in virus transmission to humans (7,8). 
Identiﬁ  cation of speciﬁ  c human activities (e.g., animal trap-
ping, hunting, or skinning) or types of exposure to animals 
(e.g., bites; exposure to feces, urine, or respiratory droplets) 
that could result in MPXV transmission from animals to 
humans has been difﬁ  cult to study because of the remote 
geographic locations involved and the retrospective nature 
of case reporting and investigation.
The introduction of MPXV into the United States in 
2003 in a consignment of wild-caught animals (exotic pets) 
from Ghana led to the occurrence and recognition of the 
ﬁ  rst human infections outside Africa (8). Although MPXV 
can be transmitted from person to person, no instances of 
interhuman transmission were documented during the US 
outbreak (3,9), which ultimately resulted in 47 conﬁ  rmed 
and probable human cases (10). Manifestations of human 
illness seen during this outbreak were considered to have 
been mild relative to those observed for persons infected 
with Central African variants of the virus (11). All human 
case-patients were documented to have handled or to have 
been near infected prairie dogs that had been temporarily 
housed in the same complex as MPXV-infected, imported 
rodents. (One case-patient recalled no speciﬁ  c exposure but 
had ample opportunity for exposure.) The infected prai-
rie dogs were sold as pets, and most ended up in private 
homes. In this environment, persons had diverse opportuni-
ties for exposure to infected animals, varying from being in 
the same room with an infected animal to cleaning the cage 
of an infected animal. In addition, several animals were 
transported to veterinary clinics for evaluation after they 
became ill, which increased the potential range of human 
exposures to infected animals. The US outbreak provides 
a means to identify activities or types of direct or indirect 
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exposure to infected animals that may have been associated 
with increased risk for MPXV transmission from animals 
to humans.
A case–control study was conducted to evaluate risk 
factors for infection among persons exposed to MPXV-in-
fected prairie dogs during the US outbreak in 2003. This 
study constituted a single arm of a multiobjective investiga-
tion exploring questions related to development of immune 
responses, infection sequelae, and the relationship between 
route of infection to MPXV and clinical outcomes. The pur-
poses of this study were to identify independent risk factors 
associated with MPXV infection and disease in humans and 
to examine the role of previous smallpox vaccination and 
age in shaping human susceptibility to MPXV infection.
Patients and Methods
Human Study Participants
The protocol for this study (part of the multi-objec-
tive study) was reviewed and approved by the institutional 
review board for human subjects research at the Centers 
for Disease Control and Prevention (CDC) (Atlanta, GA, 
USA). Approval was received (by deferral) from partner in-
stitutions in Wisconsin (Wisconsin Department of Health 
and Family Services), Illinois (Illinois Department of Public 
Health), Indiana (Indiana State Department of Health), Kan-
sas (Department of Health and Environment), and Georgia 
(Emory University). No monetary incentives or other forms 
of compensation were provided to study participants.
Deﬁ  nitions and Participant Enrollment
The 47 persons who met criteria for conﬁ  rmed or prob-
able MPXV infection on the basis of a combination of clini-
cal symptoms, exposure information, and laboratory criteria 
(12–14) (www.cdc.gov/ncidod/monkeypox/casedeﬁ  nition.
htm), and who had exposure to an infected prairie dog, were 
considered eligible for enrollment as study case-patients. 
Standardized case deﬁ   nitions were used to assign con-
ﬁ  rmed and probable case status (Table 1). Persons deﬁ  ned 
as having probable cases were those who had illness on-
set <21 days of exposure to MPXV who experienced fever 
(>37.4°C) and vesicular pustular rash, or rash (potentially 
uncharacterized) plus had immunoglobulin (IgM) to ortho-
poxvirus. MPX cases were conﬁ  rmed on the basis of any 
of the following laboratory ﬁ  ndings from clinically derived 
specimens: MPXV isolation, detection of MPXV-speciﬁ  c 
nucleic acid signatures, positive electron microscopy ﬁ  nd-
ings, or positive immunohistochemical ﬁ  ndings (the last 2 
in the absence of other orthopoxvirus virus exposures).
Persons eligible for enrollment as study controls were 
those who 1) had exposure to an infected prairie dog ei-
ther in a household or workplace setting, 2) did not acquire 
MPX disease (i.e., did not meet the clinical criteria for 
MPX disease as outlined in the case deﬁ  nition), and 3) did 
not show signs of infection in the absence of disease (i.e., 
were negative for IgM to orthopoxvirus).
Local health department personnel contacted potential 
study case-patients by telephone to ascertain their willing-
ness to participate in the study and to request the names 
of potential family or social contacts. Persons who volun-
teered were then enrolled in person at the time of interview, 
and written consent was obtained. Thirty case-patients and 
35 potential controls ultimately consented to participate in 
the study.
Three persons enrolled as potential controls were 
found to have elevated levels of IgM to orthopoxvirus. 
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Table 1. Criteria used to define categories of study participants, monkeypox virus outbreak, United States, 2003* 
Criteria met  Study 
classification
Classification by 
case definition†  Epidemiologic‡ Clinical§ Laboratory¶ 
Confirmed Yes Yes  Yes#  Case
Probable Yes  Yes (fever with vesicular pustular rash, or 
rash of unspecified type plus IgM) 
No (if rash type 
unspecified, IgM 7–56 d 
after rash onset) 
Not included  Suspect Yes  No (fever or rash of unspecified type)  No
Control** Not a case  Yes No No
Infected but not 
diseased
Unclassified  Yes  No No (IgM detected at time 
of study) 
*IgM, immunoglobulin M. 
†Available from www.cdc.gov/ncidod/monkeypox/casedefinition.htm, January 2004 (3,12,13). 
‡Epidemiologic criteria for classification of monkeypox cases included exposure to an exotic or wild mammalian pet (obtained on or after the known 
importation event) exhibiting signs of illness (e.g., conjunctivitis, respiratory symptoms, and rash); exposure to an exotic or wild mammalian pet that had 
been exposed to an animal infected with monkeypox; or exposure to a suspected, probable, or confirmed human case of monkeypox. 
§Clinical criteria were rash (macular, papular, vesicular, or pustular; generalized or localized; discrete or confluent) plus fever (subjective or measured 
temperature >99.3°F [>37.4°C]), plus >2 other signs and symptoms (chills and/or sweats, headache, backache, lymphadenopathy, sore throat, cough, 
shortness of breath), all beginning <21 d after last possible exposure. 
¶Laboratory criteria included culture of monkeypox virus, or demonstration of monkeypox virus DNA by PCR from patient clinical specimens, or 
demonstration of virus morphologically consistent with an orthopoxvirus by electron microscopy or immunohistochemical testing methods (in the absence 
of exposure to another orthopoxvirus). 
#Positive laboratory findings were sufficient to confirm a monkeypox case in the absence of complete clinical or epidemiologic history. 
**Persons investigated but ruled out as having monkeypox virus infections were eligible to enroll in the study as controls; additional controls were 
identified as in Patients and Methods. RESEARCH
These persons were excluded as controls and were clas-
siﬁ  ed as MPXV infected without clinical disease. These 3 
infected but not diseased case-patients were retained in a 
separate category to allow assessment of MPXV infection, 
as well as MPX disease, as an outcome measure.
MPXV-infected Prairie Dogs
A prairie dog was deﬁ  ned as being MPXV infected 
if tissues obtained postmortem were positive for MPXV 
DNA by culture or PCR (15). Alternatively, in the absence 
of laboratory testing, the animal was deﬁ  ned as being in-
fected if it had signs and symptoms of MPXV infection and 
was housed at a facility where other animals known to have 
been MPXV infected were also kept (5,16). 
Data Collection
Beginning in late July 2003 (≈40 days after illness on-
set of the last known human MPX case), face-to-face inter-
views were conducted with case-patients and controls. A 
standardized questionnaire was used to obtain information 
regarding demographic proﬁ  le, exposure to potentially in-
fected animals and infected humans, signs and symptoms 
of illness, and factors that might affect susceptibility, in-
cluding smallpox vaccination history. The data used in this 
study pertaining to type of animal exposure have been sum-
marized (10).
Blood Collection and Serologic Analysis
At the time of interview, a blood sample was requested 
from all study participants for detection of antibodies to or-
thopoxvirus and investigation of cellular immunity. Dona-
tion of a blood specimen was not required for enrollment in 
this study, but those specimens that were obtained were as-
sayed for IgG and IgM reactive with orthopoxvirus antigen 
(vaccinia) according to the methods of Karem et al. (12).
Data Analysis
Demographic and medical history data were analyzed 
as dichotomous categorical variables (i.e., present vs. ab-
sent). Two classiﬁ  cation schemes were used for age groups; 
one grouped participants according to whether they were 
adults (>18 years of age) or children (<18 years of age) and 
the other grouped participants according to whether they 
would have had an opportunity to have received smallpox 
vaccine as a routine childhood immunization (>31 and <31 
years of age, respectively). Routine smallpox vaccinations 
stopped in the United States in 1972. Regarding the setting 
in which the exposure occurred, if a participant indicated 
he or she was exposed at home and an additional setting, 
home was noted as the principle setting, otherwise the re-
sponse was left as recorded. Occupation was stratiﬁ  ed into 
nonanimal-related versus animal-related. Animal-related 
occupations were veterinarian, veterinarian technician or 
assistant, or pet store employee. Responses from partici-
pants who indicated exposure to >1 infected prairie dog 
were combined into 1 response; afﬁ  rmative responses were 
selected over negative responses when exposure to differ-
ent animals was not uniform.
Odds ratio (OR) with 95% conﬁ  dence interval (CI) was 
calculated to examine associations between disease status 
and exposure variables (e.g., age and smallpox vaccination 
status). Multiple logistic regression analysis was used to 
obtain ORs adjusted for the effect of smallpox vaccination 
(17) and to examine the risk for disease or infection associ-
ated with given exposures. The level of statistical signiﬁ  -
cance established for the analysis was p<0.05. The small 
size of the study population precluded further assessment 
of independent risk factors. All statistical analyses were 
performed by using SAS version 9.1 (SAS Institute, Cary, 
NC, USA).
Results
Characteristics of Case-Patients and Controls
Sixty-one persons from 4 states affected during the 
MPX outbreak were enrolled in the study (Table 2). The 
2 categories of MPX case-patients evaluated were persons 
who met the epidemiologic case deﬁ  nition for conﬁ  rmed or 
probable MPX (case-patients, n = 30) and persons who did 
not have illness meeting the case inclusion criteria but who 
had elevated levels of IgM to orthopoxvirus at the time of 
enrollment and sampling (infected but not diseased [IBND] 
patients, n = 3). Twenty-eight study controls were identi-
ﬁ  ed from the pool of enrollees. All case-patients and con-
trols had exposure to ill or infected prairie dogs; 4 persons 
reported exposure to other potentially infected animals 
(i.e., African rodents).
Most persons enrolled were >18 years of age at the 
time of study initiation (Table 2). The mean age of case-
patients at study enrollment (25.0 years) was signiﬁ  cantly 
lower than that of controls (33.3 years; 2-sided p = 0.013, 
by Student t test); the median ages of the 2 groups were 27.0 
and 36.5 years, respectively. Only 6 case-patients (20%), 3 
IBND case-patients (100%), and 15 controls (53.6%) re-
ported having had >1 smallpox vaccinations (Figure 1). All 
but one of the smallpox-vaccinated participants was >31 
years of age at the time of the study, which is consistent 
with their having received routine vaccination before the 
1972 abandonment of this practice in the United States 
(18). The only vaccinated study participant <31 years of 
age, a control, had been vaccinated as a child as a precau-
tion for international travel.
Characteristics of IBND Patients
Three persons classiﬁ  ed as MPX IBND patients were 
adults (mean age 40.7 years, median age 38.0 years), and all 
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reported having had >1 smallpox vaccination before 1972; 
2 had visible vaccination scars. Symptoms of systemic ill-
ness (chills, sweats, myalgias) developed in all 3 patients 
in the 21 days after last known exposure to an MPX-in-
fected prairie dog (Table 2), but classic MPX disease (1 
reported papular rash without fever and 2 had fever without 
lesions or rash) did not develop. Two persons reported hav-
ing touched infected prairie dogs (handled >1 infected ani-
mal), and the third had only indirect exposure to an infected 
animal (touched soiled bedding near an infected animal); 
none reported a bite or scratch from an ill prairie dog. The 
settings in which these persons were exposed differed for 
each person.
Risk Factors for Acquiring MPX
Evaluation of associations between exposure variables 
and MPX disease outcomes with inclusion of unadjusted 
OR, adjusted OR (aOR, adjusted for history of smallpox 
vaccination), and 95% CI is shown in Table 3. Results re-
lating to MPX disease as an outcome measure (i.e., that 
excluded the 3 IBND patients from the case group) are 
shown, unless results were qualitatively different when the 
3 IBND patients were included. In those instances, results 
are reported for the diseased plus the 3 IBND patients.
When not considering participant age or exposure his-
tory, a history of remote smallpox vaccination (>25 years 
previous) was protective against acquisition of MPX illness 
(OR 0.2, 95% CI 0.1–0.7). However, smallpox vaccination 
status was highly correlated with age (Spearman rank-order 
correlation r2 = 0.809, p<0.001), and its effect independent 
of age could not be assessed. Age group and sex did not 
differ between case-patients and controls.
Several types of direct exposure (touching or receiv-
ing a bite or scratch sufﬁ  cient to break the skin) and indi-
rect exposure (nontactile) with infected animals were as-
sociated with risk for MPX. Regarding direct exposures, 
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Table 2. Characteristics of monkeypox case-patients and controls selected from the population of persons exposed, monkeypox virus
outbreak, United States, 2003 
Study classifications, no. (%) 
Characteristic Case-patients
Case-patients infected 
but not diseased  Controls
State
  Illinois  8 (26.7)  1 (33.3)  8 (28.6) 
  Indiana  10 (33.3)  1 (33.3)  17 (60.7) 
 Kansas  1  (3.3)  0 0
  Wisconsin  11 (36.7)  1 (33.3)  3 (10.7) 
Age, y 
<18 10 (33.3)  0 7 (25.0) 
  >18  20 (66.7)  3 (100)  21 (75.0) 
History of smallpox vaccination 
  Yes  6 (20.0)  3 (100)  15 (53.6) 
  No  24 (80.0)  0 13 (46.4) 
Setting in which exposure occurred* 
  Home  18 (60.0)  1 (33.3)  17 (60.7) 
  Neighbor’s home  3 (10.0)  0 6 (21.4) 
  Pet store  2 (6.7)  1 (33.3)  1 (3.6) 
  Veterinary clinic  7 (23.3)  1 (33.3)  4 (14.3) 
Exposure source†‡ 
  Prairie dog (PD)  30 (100)  3 (100)  28 (100) 
  PD and African animal  1 (3.3)  1 (33.3)  2 (7.1) 
  PD and other animal  1 (3.3)  0 2 (7.1) 
  Only other animal  0 0 0
Symptoms postexposure 
  Fever  28§ (93.3)  2 (66.7)  4 (14.3) 
  Rash  30 (100)  1 (33.3)  7 (25.0) 
  Lymphadenopathy  20 (66.7)  1 (33.3)  4 (14.3) 
  Mouth sores  8 (26.7)  0 1 (3.6) 
 Conjunctivitis  4  (13.3)  0 0
  Cough  17 (56.7)  0 2 (7.1) 
Total 30 3 28
*Indicates principal setting for exposure. 
†Reported exposures pertain to animals with laboratory-confirmed monkeypox infections (15) or ones that had lesion-producing illnesses plus prior 
exposure to a confirmed infected animal. African animals included dormice, giant Gambian rats, jerboas, hedgehogs, striped mice, and pygmy mice. 
‡Includes all reported exposures; categories not mutually exclusive. 
§Self-reported information for fever was indicated as unknown or was missing for 2 persons who had laboratory-
confirmed monkeypox infections. RESEARCH
having touched a sick animal was signiﬁ  cantly associated 
with development of MPX (OR 3.8, 95% CI 1.2–11.7) 
regardless of smallpox vaccination status (aOR 4.0, 95% 
CI 1.2–13.4). Having received a scratch from an infected 
animal was signiﬁ  cantly associated with disease but only 
when not adjusted for smallpox vaccination (OR 5.6, 95% 
CI 1.1–28.6; aOR 3.9, 95% CI 0.7–21.1). Among 9 persons 
who were scratched by an infected prairie dog, 1 had had 
prior smallpox vaccination. Only 1 MPX case-patient (a 
previously vaccinated person) reported a prairie dog bite; 
no controls reported having been bitten.
Among indirect exposures, having been near an in-
fected animal (deﬁ  ned as having come within 6 feet of the 
animal without touching it) was not associated with devel-
opment of MPX. Having cleaned the cage or touched used 
bedding of an infected animal was signiﬁ  cantly associated 
with MPX development, both with and without adjustment 
for prior smallpox vaccination (OR 5.3, 95% CI 1.5–18.9; 
aOR 5.3, 95% CI 1.4–20.7). Also, regardless whether ex-
posure was direct or indirect, having had daily exposure to 
the animal while it was ill was signiﬁ  cantly associated with 
MPX developing (OR 3.8, 95% CI 1.2–11.7; aOR 4.0, 95% 
CI 1.2–13.4).
When MPX infection (n = 33, 30 patients and 3 IBND 
patients), rather than MPX disease, was chosen as the 
outcome measure, only direct (touch) exposure (OR 5.0, 
95% CI 1.4–17.6; aOR 4.9, 95% CI 1.3–17.9) and having 
cleaned the cage or touched used bedding of an infected 
animal (OR 3.6, 95% CI 1.2–10.7; aOR 3.6, 95% CI 1.2–
11.4) were signiﬁ  cantly associated with infection. Again, 
regardless of age or exposure characteristics, reported his-
tory of prior, remote smallpox vaccination was protective 
against MPX infection (OR 0.3, 95% CI 0.1–0.9).
Exposure Characteristics of Vaccinated 
and Unvaccinated Adults and Children
Because the study population was too small to support 
multivariate analysis, we were unable to evaluate associa-
tions between disease outcomes and individual exposures 
while controlling for other potentially contributing factors. 
Therefore, we evaluated types of exposures to prairie dogs 
among different study subgroups (smallpox-vaccinated 
persons vs. unvaccinated persons, and adults vs. children) 
to examine whether differences in proportions exposed 
could have biased observed associations between disease 
acquisition and previous smallpox vaccination or age.
The proportion of smallpox-vaccinated and unvacci-
nated study participants who reported various exposures 
to infected prairie dogs is shown in Figure 2, panel A. For 
all but 1 category of exposure, a smaller proportion of 
smallpox-vaccinated persons reported exposure than un-
vaccinated persons, which potentially introduced bias in 
interpreting lack of prior vaccination as a risk factor for 
disease. The exception, having been bitten by an infected 
animal, was reported by only 1 person, a smallpox-vacci-
nated person in whom relatively benign MPX developed. 
This person was not hospitalized and had <25 lesions. 
Unvaccinated persons had a higher frequency of scratches 
and breaks in the skin (10 [27.0%]) than did smallpox-vac-
cinated persons (1 [4.8%]; p = 0.044, by 2-tailed Fisher ex-
act test). A similar evaluation of exposure characteristics 
in children and adults indicated that while certain expo-
sures were more common in children than in adults (e.g., 
having had an infected animal as a pet, having had daily or 
direct exposure to an infected animal) (Figure 2, panel B), 
neither age category uniformly had higher proportionate 
exposure.
Risk Factors for Vaccinated and 
Unvaccinated Participants
To evaluate potential differences in risks for MPX dis-
ease acquisition between smallpox-vaccinated and unvac-
cinated persons, case-patients and controls were stratiﬁ  ed 
by vaccination status and exposures were examined. No 
exposure or demographic variables were associated with 
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Figure 1. Age distribution of monkeypox virus–infected case-
patients (A) and controls (B) and smallpox vaccination status. No 
study participants reported having received a smallpox vaccination 
within 25 years of August 2003. Risk Factors for Human Monkeypox, United States
infection or disease status when participants were stratiﬁ  ed 
by smallpox vaccination status. However, power to detect 
statistically signiﬁ  cant associations was limited because of 
small numbers.
Discussion
Although complexity of exposures varied among per-
sons affected during the 2003 outbreak of MPX in the Unit-
ed States, prairie dogs were the common vehicle implicated 
in virus transmission to humans (3,8,19,20). The goal of 
this study was to identify host characteristics and speciﬁ  c 
types of exposure to infected animals that were associated 
with increased risk for infection or disease. Results demon-
strated that several types of direct and indirect exposures to 
infected animals (including being scratched by an infected 
animal, handling one, or cleaning a soiled cage) were as-
sociated with increased risk of acquiring MPX. The ob-
servation that daily exposure to infected prairie dogs was 
associated principally with disease, and not merely with 
infection, suggests that increasing the intensity or duration 
of exposure to viral inoculum may increase the probability 
for overt illness.
Insights into potential transmission mechanisms by 
which handling or exposure to excretions or secretions of 
an infected animal could result in human infection come 
from pathology of MPXV infection in prairie dogs. Im-
munohistochemical evaluation of lesion and organ tissue 
obtained from prairie dogs that became ill during the US 
outbreak showed abundant viral antigen in surface epithe-
lial cells at ulcerated sites on the tongue, conjunctiva, and 
throughout the lungs (5). Results of experimental infection 
studies of prairie dogs with MPX mirrored these observa-
tions (16), which suggests that respiratory, mucocutaneous, 
and transdermal routes of virus transmission are plausible, 
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Table 3. Smallpox vaccination status, demographic characteristics, and potential exposures to infected prairie dogs among case-
patients and controls, monkeypox virus outbreak, United States, 2003* 
Characteristic Case-patients, no. (%)  Controls, no. (%)  OR (95% CI)  aOR (95% CI) 
Smallpox vaccination 
  Yes  6 (20.0)  15 (53.6)  0.2 (0.1–0.7) 
  No  24 (80.0)  13 (46.7) 
Age, y† 
<18 10 (33.3)  7 (25.0)  1.5 (0.5–4.7)  0.6 (0.2–2.4) 
  >18  20 (66.7)  21 (75.0) 
Sex 
  Female  17 (56.7)  16 (57.1)  1.0 (0.3–2.8)  0.9 (0.3–2.7) 
  Male  13 (43.3)  12 (42.9) 
Type of exposure to prairie dog(s) 
  Animal as pet 
    Yes  17 (56.7)  9 (32.1)  2.8 (0.9–8.1)  2.4 (0.8–7.4) 
  No  13  (43.3)  19  (67.9) 
  Daily exposure while animal was ill 
  Yes  23  (76.7)  13  (46.4)  3.8  (1.2–11.7)  4.0  (1.2–13.4) 
  No  7  (23.3)  15  (53.6) 
  Touched rash or eye crusts 
  Yes  18  (60.0)  11  (39.3)  2.3  (0.8–6.6)  2.2  (0.7–6.7) 
  No  12  (40.0)  17  (60.7) 
 Scratched‡ 
    Yes  9 (30.0)  2 (7.1)  5.6 (1.1–28.6)  3.9 (0.7–21.1) 
  No  21  (70.0)  26  (92.9) 
  Cleaned cage/touched bedding 
    Yes  14 (46.7)  4 (14.3)  5.3 (1.5–18.9)  5.3 (1.4–20.7) 
  No  16  (53.3)  24  (85.7) 
  Proximity, no touching§ 
    Yes  12 (40.0)  7 (25.0)  2.0 (0.6–6.2)  2.0 (0.6–6.5) 
  No  18  (60.0)  21  (75.0) 
 Direct  exposure¶ 
  Yes  23  (76.7)  13  (46.4)  3.8  (1.2–11.7)  4.0  (1.2–13.4) 
  No  7  (23.3)  15  (53.6) 
*OR, odds ratio; CI, confidence interval; aOR, adjusted OR. The aORs and 95% CIs were adjusted for history of (>1) smallpox vaccination at any time 
during case-patient’s life. 
†Routine immunization was stopped in the United States in 1972 (18), persons <33 years of age at the time of the outbreak were unlikely to have received 
prior smallpox vaccination. 
‡Scratched with a break in the skin. 
§Came within 6 feet of the prairie dog but never touched it. 
¶Direct exposure to an infected animal included having touched the animal or having received a bite or scratch from it sufficient to break the skin. RESEARCH
all of which are consistent with types of exposures impli-
cated in this study.
Although a history of smallpox vaccination was as-
sociated with diminished risk for MPXV infection in this 
study, accurately interpreting this ﬁ  nding is difﬁ  cult in the 
absence of consideration of age or exposure history. In hu-
man epidemiologic studies, age has been shown to affect 
susceptibility to MPX. Additionally, studies conducted in 
the 1980s in the Democratic Republic of the Congo (for-
mer Zaire) highlighted both age and smallpox vaccination 
status as key determinants of MPX acquisition in humans; 
unvaccinated children 5–15 years of age, those old enough 
for autonomous interaction with animals, had the highest 
rates of MPXV infection (21–23). In these studies, a prior 
history of smallpox vaccination within 3–19 years before 
MPXV exposure provided up to 85% protection against 
MPXV infection across various age classes. In our study, 
no study participants received smallpox vaccination with-
in 25 years of MPX exposure, and the role of vaccination 
could not be evaluated independent of age because there 
were few unvaccinated older persons in the study popula-
tion and no vaccinated children. Lack of adequate compari-
son groups needed to discriminate between age- and vacci-
nation-related effects could emphasize potential protective 
beneﬁ  ts of remote smallpox vaccination more than older 
age at disease acquisition.
Also complicating interpretation of the role of vac-
cination in inﬂ   uencing susceptibility is our observation 
that vaccinated participants had fewer overall exposures to 
infected animals than did unvaccinated participants. Vac-
cinated persons had fewer invasive (scratch) exposures, 
which were associated with the highest case conversion 
rate (81.8%) among all measured exposures (except bite 
exposure, which was recorded only 1 time). Thus, discern-
ing whether vaccinated participants beneﬁ  ted from having 
had fewer exposures to infected animals or from residual 
smallpox vaccine–derived immunity was difﬁ  cult. The dis-
proportionate enrollment of controls in different states (e.g., 
less for Wisconsin, where many exposures occurred in vet-
erinary care settings), may have contributed to this effect. 
Because size and composition of the study population were 
insufﬁ  cient to support multivariate modeling approaches 
for assessment of vaccination status, age, and exposure as 
independent risk factors, we were unable to clearly deﬁ  ne a 
protective beneﬁ  t of remote vaccination against acquisition 
of MPXV infection.
Although suggested in 1 report (24), systematically 
collected data from patients infected with MPXV of the 
West African genetic clade during the outbreak in the Unit-
ed States have not supported a role for remote smallpox 
vaccination in mitigation of MPX disease severity (25). 
In our study, mild subclinical MPXV infections occurred 
in 3 adult study participants, all of whom were previously 
vaccinated. Whether the diminished severity was a con-
sequence of the manner of exposure, the age of the per-
son, the person’s vaccination status, or some other factor 
is unknown. No common exposure was identiﬁ  ed among 
these persons, and each reported symptoms of viral illness. 
All had evidence of a speciﬁ  c immunologic response after 
exposure to MPXV. Subclinical and asymptomatic MPXV 
infections have been suggested in both children and adults 
in other studies (21,22,24), but we provide evidence of 
mild, systemic, nonspeciﬁ  c symptoms in the context of an 
acute (IgM) antibody response. The epidemiologic role of 
such cases remains to be determined, but their identiﬁ  ca-
tion here supports the need for investigation of persons 
with nonspeciﬁ  c symptoms during future MPX outbreak 
investigations.
The route of MPXV infection (bite, mucocutaneous) 
inﬂ  uences the time course and manifestations of illness 
(10). We have assessed overall risk for infection associ-
ated with types of exposures. It is arguable that behavioral 
interactions between prairie dogs and pet owners or vet-
erinarians have no direct parallels with types of animal-hu-
man interactions that result in MPXV infections in African 
settings. However, results of this study highlight the role 
of direct physical contact and potential exposure to excre-
tions and secretions of a sick animal (urine, feces, saliva). 
These results also provide insights into how natural infec-
tions might occur in Africa (e.g., not only during prepara-
tion of carcasses, as has traditionally been suggested, but 
also through exposure to animal nests or excreta). There 
are no smallpox vaccination programs ongoing in Africa, 
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Figure 2. Characteristics of exposure to infected prairie dogs of 
A) vaccinated and unvaccinated monkeypox case-patients and 
controls and B) case-patients (adults and children) and controls. 
*Denotes statistically signiﬁ  cant differences in exposure between 
groups.Risk Factors for Human Monkeypox, United States
and smallpox vaccines currently licensed are not consid-
ered suitable for use in populations with high prevalences 
of immunocompromised persons (26,27). Behavioral inter-
ventions offer the best opportunity to prevent introduction 
of MPXV into human communities.
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